Genflow Biosciences Plc (GB:GENF)
LSE:GENF
Want to see GB:GENF full AI Analyst Report?
Top Page
Genflow Biosciences Plc
(LSE:GENF)
Select Model
Select Model
Rating:50Neutral
Price Target:
2.50 p
▲(11.11% Upside)
Action:ReiteratedDate:05/04/26
The score is held down primarily by very weak financial performance (pre-revenue, ongoing losses, negative equity, and continued cash burn). Technicals provide a meaningful offset with a clear uptrend and positive momentum, while valuation remains constrained by loss-making status and no dividend data.
Positive Factors
No financial debt
Having no financial debt meaningfully lowers refinancing and interest-rate risk for a pre-revenue biotech. This preserves flexibility to time equity or partnership financing, avoids covenants that can constrain R&D, and reduces near-term liquidity pressure across a 2–6 month horizon.
Negative Factors
Pre-revenue with operating losses
Zero reported revenue and recurring operating losses mean the business lacks internal cash generation and commercial validation. Over the next 2–6 months this maintains high execution risk, limits leverage in partner talks and necessitates external capital to sustain R&D and operations.
Read all positive and negative factors
Positive Factors
Negative Factors
No financial debt
Having no financial debt meaningfully lowers refinancing and interest-rate risk for a pre-revenue biotech. This preserves flexibility to time equity or partnership financing, avoids covenants that can constrain R&D, and reduces near-term liquidity pressure across a 2–6 month horizon.
Read all positive factors
Genflow Biosciences Plc (GENF) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£14.46M
Dividend YieldN/A
Average Volume (3M)1.73M
Price to Earnings (P/E)―
Beta (1Y)-0.27
Revenue GrowthN/A
EPS Growth29.79%
CountryUK
Employees5
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.00
Shares Outstanding535,653,200
10 Day Avg. Volume2,042,393
30 Day Avg. Volume1,733,703
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)-14.33
Price to Sales (P/S)0.00
P/FCF Ratio-5.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Genflow Biosciences Plc Business Overview & Revenue Model
Company Description
Genflow Biosciences plc operates as a biotechnology company that focuses on developing biological interventions aimed at tackling the effects of ageing, slowing or halting the ageing process, and reducing the incidence of age-related diseases with...
How the Company Makes Money
null...
Genflow Biosciences Plc Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
10
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | -150.95K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -150.95K | -1.09K | -1.20K | -1.03K | -130.00 | 0.00 |
| EBITDA | -1.27M | -2.00M | -1.59M | -1.80M | -1.33M | -988.10K |
| Net Income | -1.27M | -1.42M | -1.59M | -1.63M | -1.34M | -988.29K |
Balance Sheet | ||||||
| Total Assets | 468.38K | 452.39K | 385.91K | 1.07M | 2.62M | 276.55K |
| Cash, Cash Equivalents and Short-Term Investments | 279.44K | 111.79K | 278.68K | 683.97K | 2.36M | 224.00K |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 771.38K | 1.00M | 788.92K | 345.74K | 250.99K | 221.43K |
| Stockholders Equity | -303.00K | -550.78K | -403.01K | 725.91K | 2.37M | 55.12K |
Cash Flow | ||||||
| Free Cash Flow | -1.28M | -1.44M | -1.08M | -1.66M | -1.37M | -747.38K |
| Operating Cash Flow | -1.28M | -1.44M | -1.08M | -1.66M | -1.37M | -747.38K |
| Investing Cash Flow | 372.00 | 0.00 | 0.00 | -2.44K | -2.48K | 198.50K |
| Financing Cash Flow | 865.22K | 1.31M | 656.63K | 0.00 | 3.50M | 783.71K |
Genflow Biosciences Plc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | £14.46M | -5.57 | 377.33% | ― | ― | 29.79% | |
50 Neutral | £2.27M | -0.72 | -89.43% | ― | 91.27% | 60.98% | |
44 Neutral | £17.50M | -9.67 | -210.32% | ― | -11.43% | 23.40% | |
41 Neutral | £78.20M | -4.89 | -63.53% | ― | 198.49% | -26.66% | |
40 Underperform | £8.80M | -0.25 | -316.67% | ― | 72.17% | 79.03% | |
40 Underperform | £21.59M | -6.19 | -213.66% | ― | 13.42% | 65.63% |
* Healthcare Sector Average
GB:GENF
Genflow Biosciences Plc
2.66
1.81
212.94%
GB:OBD
Oxford BioDynamics
0.20
-0.21
-51.25%
GB:PYC
Physiomics
0.48
>-0.01
-1.04%
GB:FAB
Fusion Antibodies Plc
12.00
6.20
106.90%
GB:4BB
4basebio UK Societas
484.00
-641.00
-56.98%
GB:APTA
Aptamer Group Plc
0.60
0.23
62.16%
Genflow Biosciences Plc Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Genflow Advances SIRT6 Longevity Pipeline as Funding and Canine Trial Progress Bolster Position
Positive
Apr 30, 2026
Genflow Biosciences reported significant operational progress in 2025, highlighting its canine SLAB trial in aged beagles, which advanced without safety issues and is expected to complete by July 2026, and early partnering talks with major animal ...
Business Operations and Strategy
Genflow widens Tier-1 animal health review of canine gene therapy
Positive
Apr 28, 2026
Genflow Biosciences has expanded its network of confidentiality agreements with additional Tier-1 global animal health companies to review data from its canine SIRT6 centenarian gene therapy programme. The move follows previously disclosed positiv...
Business Operations and Strategy
Genflow Secures Fully Funded LNP Collaboration With Acuitas to Advance SIRT6 Gene Therapy
Positive
Apr 20, 2026
Genflow Biosciences has entered a strategic technology collaboration with Acuitas Therapeutics, gaining fully funded, non-dilutive access to Acuitas’ clinically validated lipid nanoparticle platform to deliver its SIRT6 mRNA payload. The dea...
Business Operations and Strategy
Genflow widens SIRT6 patent shield with muscular disease program
Positive
Apr 13, 2026
Genflow Biosciences has secured international publication of a Patent Cooperation Treaty application covering variants of the SIRT6 gene for preventing and treating muscular diseases, particularly frailty syndrome and sarcopenia. The filing detail...
Business Operations and StrategyProduct-Related Announcements
Genflow sees sustained safety and efficacy in SIRT6 beagle trial
Positive
Apr 8, 2026
Genflow Biosciences reported that three-month follow-up data from its SLAB trial in aged beagles show sustained safety and efficacy of its SIRT6 centenarian gene therapy, with no adverse events and maintained improvements across multiple functiona...
Business Operations and StrategyRegulatory Filings and Compliance
Genflow Biosciences Updates Share Capital and Voting Rights Total
Neutral
Mar 31, 2026
Genflow Biosciences has reported that its total issued share capital as of 31 March 2026 stands at 535,653,205 ordinary shares, all carrying voting rights and with none held in treasury. This updated figure sets the official denominator for invest...
Business Operations and StrategyPrivate Placements and Financing
Genflow Biosciences Raises £800,000 to Advance Gene Therapy Pipeline and Bolster Licensing Talks
Positive
Mar 5, 2026
Genflow Biosciences has raised £800,000 through a subscription of 42,105,263 new ordinary shares at 1.9p each, with one warrant attached per share, to fund the advancement of its scientific programs and extend its cash runway. The financing, ...
Business Operations and StrategyPrivate Placements and FinancingShareholder Meetings
Genflow Wins Shareholder Backing for Expanded Financing Flexibility
Positive
Mar 2, 2026
Genflow Biosciences Plc, a UK-based longevity-focused biotechnology company listed in London and on OTCQB, is developing gene therapies such as its lead candidate GF-1002, which targets aging-related conditions and is under evaluation in an aged-d...
Business Operations and StrategyPrivate Placements and Financing
Genflow Receives First Tranche of €4m Wallonia Grant to Advance GF-1002
Positive
Mar 2, 2026
Genflow Biosciences Plc, a longevity-focused gene therapy developer based in the UK with Belgian RD operations, is advancing its lead asset GF-1002, which targets age-related decline via a centenarian SIRT6 variant and is under evaluation in canin...
Business Operations and StrategyProduct-Related Announcements
Genflow Reports Positive Interim Data for SIRT6 Gene Therapy in Aged Dogs
Positive
Feb 12, 2026
Genflow Biosciences has reported positive preliminary interim results from its SLAB clinical trial testing its proprietary SIRT6 centenarian gene therapy in 24 aged beagle dogs. The randomized, blinded study found that all treatment groups showed ...
Business Operations and StrategyPrivate Placements and FinancingShareholder Meetings
Genflow Seeks Shareholder Mandate for Potential Equity Raise to Advance Gene Therapy Pipeline
Neutral
Feb 11, 2026
Genflow Biosciences plans to seek shareholder approval at a 2 March 2026 general meeting to authorize the issue of up to 188,947,368 new ordinary shares, equivalent to about 38% of its current share capital. The authority would allow the board to ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.